SL Science Seeks FDA Orphan Drug Status for Gamma Delta T Cell Therapy in Glioblastoma
TipRanks (Fri, 10-Jul 9:08 AM ET)
Globe Newswire (Fri, 10-Jul 8:00 AM ET)
SL Science Highlights Strategic Shift and Major Pipeline Progress Amid Wider Losses in FY 2025
Market Chameleon (Mon, 22-Jun 3:06 AM ET)
SL Science Holding Limited Reports Full Year 2025 Financial Results
Globe Newswire (Thu, 18-Jun 5:13 PM ET)
Market Chameleon (Wed, 17-Jun 3:05 AM ET)
Biotech Bulls Stampede as Clinical Wins and Milestones Fuel Momentum
Globe Newswire (Tue, 16-Jun 10:18 AM ET)
SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.
SL Science Holding Limited - trades on the NASDAQ stock market under the symbol SLBT.
As of July 13, 2026, SLBT stock price declined to $4.33 with 33,264 million shares trading.
SLBT has a market cap of $2.43 billion. This is considered a Mid Cap stock.
SLBT support price is $3.23 and resistance is $6.23 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SLBT shares will trade within this expected range on the day.
